biologically active compounds from non-N. brasiliensis clinical isolates, we isolated a new antifungal compound, designated as transvalencin A (Fig. 1) , from the mycelial cake of a clinical isolate of Nocardia sp. strain IFM 10065 obtained from a patient with actinomycotic mycetoma. This paper describes the taxonomy of the producing organism, fermentation, isolation, physicochemical properties, and biological activities of the antibiotic. Structural elucidation of the compound is reported in a subsequent paper. USA) with 1% glucose and 1% glycerol for 1 week at bacterial strain was cultured on brain heart infusion (BHI;
Physiological and biochemical characterization of the strain was done by method described previously.
Decomposition of various compounds such as adenine and casein were undertaken using methods of GORDON et al.13) Acid production tests using various carbohydrates, utilization of organic acids, and growth temperature were determined by the modified method of POONWAN et al.14)
Whole cell hydrolysates were analyzed for diaminopimelic acid (DAP) isomers and for cell wall sugars using thin layer chromatography (TLC indicated that it was a strain of N. transvalensis (Table 1) .
Thus IFM 10065 was identified as N. transvalensis based on these phylogenetic, physiological, and biochemical characteristics. Fermentation, Isolation and Physico-chemical Properties After 7 days' incubation, one half volume of methanol was added to the mycelial cake; it was incubated for another 3 hours to kill the Nocardia and extract the active compound. The extract was filtered and concentrated in vacuo. After addition of 100-ml water to the concentrated fraction, it was extracted with the same volume of ethyl acetate. The extract was concentrated in vacuo: a crude residue was subjected to silica gel column chromatography using CHCl3. The combined active fractions were purified further using silica gel column chromatography with a mixture of toluene and ethyl acetate (3:1). The active fractions were further purified by preparative thin layer chromatography (TLC) using the mixture of toluene: ethyl acetate (3:1) as eluent. The active compound was applied to Sephadex LH-20 column chromatography (CHCl3: methanol=1:1). The purified compound was obtained by preparative reverse phase HPLC 5ml/minute, 250nm; Jasco Inc.). Final purification was 5ml/minute, 250nm; Jasco Inc.) to obtain 7.2mg of transvalencin A. 
Biological Properties

